| Drug Name | )PREZISTA(DARUNAVIR |
|---|---|
| Drug Class |
Anti-viral
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Infectious disease
|
| Risk |
Increased risk of treatment failure and an increased risk of mother to child transmission of HIV infection due to low exposure values of darunavir and cobicistat during the second and third trimesters of pregnancy |
| Dear Healthcare provider letter DHPC |
|